At ACADIA, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

SAN DIEGO --(BUSINESS WIRE)--May 28, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Business Officer. Mr.
- Top-line results expected in 3Q20 SAN DIEGO --(BUSINESS WIRE)--May 26, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that following positive feedback from the U.S. Food and Drug Administration the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3 studies evaluating
SAN DIEGO --(BUSINESS WIRE)--May 21, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS) disorders will be highlighted at the 2020